Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

21. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression

Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Stay at home Only go outside for food, health reasons (...) or work (but only if you cannot work from home) If you go out, stay 2 metres (6ft) away from other people at all times Wash your hands as soon as you get home Do not meet others, even friends or family. You can spread the virus even if you don’t have symptoms. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression Benzodiazepines and opioids can both cause respiratory depression, which can be fatal if not recognised in time. Only prescribe together

2020 MHRA Drug Safety Update

22. Vagal nerve stimulation for epilepsy and depression

Vagal nerve stimulation for epilepsy and depression Vagal nerve stimulation for epilepsy and depression | Washington State Health Care Authority Toggle search Toggle navigation Announcement Menu Apple Health Eligibility Manual Search Close menu Search form Search all of HCA Search Health care services and supports Search Billers, providers, & partners Search Employee & retiree benefits Search About HCA Search Vagal nerve stimulation for epilepsy and depression Vagal nerve stimulation (...) for epilepsy and depression Public comment period extended. Public comment on the vagal nerve stimulation draft report has been extended until close of business, March 30, 2020. Submit all comments to: Vagal nerve stimulation (VNS) for epilepsy and depression was first reviewed by the HTA in 2009. In 2013, a review of VNS medical literature was conducted to determine if newly available evidence published since 2008 was likely to change the original coverage determination. The technology was not selected

2020 Washington Health Care Authority

23. End-stage Renal Disease and Depression: A Systematic Review

End-stage Renal Disease and Depression: A Systematic Review Management Briefs eBrief-no169 -- End-stage Renal Disease and Depression: A Systematic Review Talk to the Veterans Crisis Line now An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you're connecting (...) to the official website and that any information you provide is encrypted and sent securely. Search Search the ORD website Button to search HSRD Contact us TTY: 711 × We're here anytime, day or night — 24/7 If you are a Veteran in crisis or concerned about one, connect with our caring, qualified responders for confidential help. Many of them are Veterans themselves. Get more resources at . » » » Management Briefs eBrief-no169 -- End-stage Renal Disease and Depression: A Systematic Review Health Services

2020 Veterans Affairs - R&D

24. But I am not Depressed: Antidepressants for Irritable Bowel Syndrome

But I am not Depressed: Antidepressants for Irritable Bowel Syndrome Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) January 20, 2020 But I am not Depressed: Antidepressants for Irritable Bowel Syndrome Clinical Question: Do antidepressant medications improve irritable bowel syndrome (IBS) symptoms? Bottom Line: Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) may improve overall IBS symptoms. About 55% of patients treated with TCAs or SSRIs will benefit compared to ~35% with placebo. Only TCAs improve abdominal pain for ~60% of patients compared to ~30% with placebo. TCA

2020 Tools for Practice

25. Mental Health: Targeted School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms

Mental Health: Targeted School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms Mental Health: Targeted School-Based CBT | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) February 2019 Audience Adolescents and Young Adults Children/Infants Setting School (...) Strategy Counseling Health Education Mental Health: Targeted School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms Tabs Snapshot Summary of CPSTF Finding The targeted school-based cognitive behavioral therapy programs to reduce depression and anxiety symptoms among school-aged children and adolescents who are assessed to be at increased risk for these conditions. The CPSTF also recommends , and and CBT to reduce psychological harm from traumatic events among

2020 Community Preventive Services Task Force

26. Mental Health: Universal School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms

Mental Health: Universal School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms Mental Health: Universal School-Based CBT | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) February 2019 Audience Adolescents and Young Adults Children/Infants Setting School (...) Strategy Counseling Health Education Mental Health: Universal School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms Tabs Snapshot Summary of CPSTF Finding The universal school-based cognitive behavioral therapy programs to prevent or reduce depression and anxiety symptoms among school-aged children and adolescents. The CPSTF also recommends for students who are assessed to be at increased risk for these conditions, and and CBT to reduce psychological harm from

2020 Community Preventive Services Task Force

27. Depression and post-traumatic stress during major social unrest in Hong Kong: a 10-year prospective cohort study. (Abstract)

Depression and post-traumatic stress during major social unrest in Hong Kong: a 10-year prospective cohort study. Hong Kong has been embroiled in increasingly violent social unrest since June, 2019. We examined the associated population mental health burden, risk factors, and health-care needs.In a population-based prospective cohort, adult participants aged 18 years or older were assessed at nine timepoints from 2009. Probable depression was measured using the Patient Health Questionnaire-9 (...) (score ≥10) and suspected post-traumatic stress disorder (PTSD) by the PTSD Checklist-Civilian Version (score ≥14), plus direct exposure to traumatic events related to the ongoing social unrest. We used multivariable logistic regression to identify factors associated with both outcomes, adjusting for doctor-diagnosed depression or anxiety disorders before the unrest. On the basis of routine service statistics and respondents' intention to seek professional care, we projected the number of additional

2020 Lancet

28. Esketamine (Spravato) - major depression

Esketamine (Spravato) - major depression Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/578240/2019 EMEA/H/C/004535 Spravato (esketamine) An overview of Spravato and why (...) it is authorised in the EU What is Spravato and what is it used for? Spravato is a medicine used to treat adults with major depression that is resistant to treatment. It is used in combination with an SSRI or SNRI medicine (other antidepressants) when at least two other treatments have failed. Spravato contains the active substance esketamine. How is Spravato used? Spravato is available as a nasal spray to be used by the patient in a clinic or doctor’s office, under the direct supervision of a healthcare

2020 European Medicines Agency - EPARs

29. Guided self-help for depression in autistic adults: the ADEPT feasibility RCT Full Text available with Trip Pro

Guided self-help for depression in autistic adults: the ADEPT feasibility RCT Guided self-help for depression in autistic adults: the ADEPT feasibility RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1

2020 NIHR HTA programme

30. Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT Full Text available with Trip Pro

Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation (...) or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} The research programme has improved our understanding of when patients experience improvement and found that sertraline did not reduce depressive symptoms at 6 weeks but did reduce anxiety symptoms. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & . Larisa Duffy 1, * , Gemma Lewis 1

2020 NIHR HTA programme

31. Effectiveness of an Interventional Package on the Level of Anxiety, Depression, and Fatigue among Patients with Cervical Cancer. Full Text available with Trip Pro

Effectiveness of an Interventional Package on the Level of Anxiety, Depression, and Fatigue among Patients with Cervical Cancer. To evaluate the effectiveness of interventional package on the level of anxiety, depression, and fatigue.The study was conducted in room no. 5, first floor, B Block, Department of Radiotherapy, Nehru Hospital, Postgraduate Institute of Medical Education and Research, Chandigarh Quasi experimental pretest-posttest design was used in the study. A total of 60 patients (...) receiving radiotherapy/chemotherapy were assigned in two groups of 30 each, through total enumeration sampling technique. The tools used for the study were Zung Anxiety Scale, Beck Depression inventory, and Fatigue Scale. The protocol used for the study includes the Jacobson's Progressive muscle relaxtion technique, counsling and home care techniques.Sociodemographic variables and clinical profile of participants in both groups were comparable. Interventional package significantly reduces the anxiety

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

32. The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model. (Abstract)

The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model. Most guidelines for major depressive disorder recommend initial treatment with either a second-generation antidepressant (SGA) or cognitive behavioral therapy (CBT). Although most trials suggest that these treatments have similar efficacy, their health economic implications are uncertain.To quantify (...) the cost-effectiveness of CBT versus SGA for initial treatment of depression.Decision analytic model.Relative effectiveness data from a meta-analysis of randomized controlled trials; additional clinical and economic data from other publications.Adults with newly diagnosed major depressive disorder in the United States.1 to 5 years.Health care sector and societal.Initial treatment with either an SGA or group and individual CBT.Costs in 2014 U.S. dollars, quality-adjusted life-years (QALYs

2019 Annals of Internal Medicine

33. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts

Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts Running head: APA GUIDELINE FOR THE TREATMENT OF DEPRESSION i Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts American Psychological Association Guideline Development Panel for the Treatment of Depressive Disorders Adopted as APA Policy Feb. 16, 2019 Author Notes Members of the Guideline Development Panel for the Treatment of Depressive Disorders were John R. McQuaid (chair (...) First Street, NE, Washington, DC 20002-4242. E-mail: cpg@apa.org. APA GUIDELINE FOR THE TREATMENT OF DEPRESSION ii Abstract The American Psychological Association (APA) developed this clinical practice guideline to provide recommendations for the treatment of depressive disorders (including major depression, subsyndromal depression, and persistent depressive disorder). It addresses three developmental cohorts: children and adolescents; general adults; and older adults (ages 60 and over). Ten

2019 American Psychological Association

34. Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial (Abstract)

Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial Patients with acute coronary syndrome (ACS) and elevated depressive symptoms are at increased risk for recurrent cardiovascular events and mortality, worse quality of life, and higher health care costs. These observational findings prompted multiple scientific panels to advise universal depression screening in survivors of ACS prior to evidence from randomized screening (...) trials.To determine whether systematically screening for depression in survivors of ACS improves quality of life and depression compared with usual care.A 3-group multisite randomized trial enrolled 1500 patients with ACS from 4 health care systems between November 1, 2013, and March 31, 2017, with follow-up ending July 31, 2018. Patients were eligible if they had been hospitalized for ACS in the previous 2 to 12 months and had no prior history of depression. All analyses were performed on an intention

2019 EvidenceUpdates

35. Interest in participation of the development of a core outcome set for treatment of perinatal depression

Interest in participation of the development of a core outcome set for treatment of perinatal depression Interest in participation of the development of a core outcome set for treatment of perinatal depression We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Interest in participation of the development of a core outcome set for treatment (...) of perinatal depression Share: Reading time approx. 4 minutes SBU is developing a Core Outcome Set on treatment of perinatal depression and we would like your help! Perinatal depression is depression experienced during pregnancy (known as ante or prenatal depression) or after childbirth (known as postnatal depression). A more detailed description of the project is available in the . This project has been registered in the A Core Outcome Set (COS) is an agreed minimum set of outcomes or outcome measures

2019 Swedish Council on Technology Assessement

36. Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update

Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update | CADTH.ca Find the information you need Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines (...) – An Update Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update Last updated: June 28, 2019 Project Number: RC1142-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of repetitive transcranial magnetic stimulation for patients with treatment-resistant depression? What is the cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

37. Bright Light Therapy for Depression: Clinical Effectiveness

Bright Light Therapy for Depression: Clinical Effectiveness Bright Light Therapy for Depression: Clinical Effectiveness | CADTH.ca Find the information you need Bright Light Therapy for Depression: Clinical Effectiveness Bright Light Therapy for Depression: Clinical Effectiveness Last updated: August 28, 2019 Project Number: RB1391-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of bright (...) light therapy in patients with major depressive disorder or persistent depressive disorder? Key Message One systematic review, and two randomized controlled trials were identified regarding the clinical effectiveness of bright light therapy in patients with major depressive disorder or persistent depressive disorder. Files Rapid Response Summary of Abstracts Published : August 28, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

38. Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment

Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment | CADTH.ca Find the information you need Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Internet-Delivered Cognitive Behavioural Therapy for Major (...) Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Last updated: March 19, 2019 Project Number: OP0534-000 Product Line: Research Type: Device Result type: Report Major depressive disorder (MDD) is the occurrence of one or more major depressive episodes that last at least two weeks. Anxiety disorders include a range of conditions, including generalized anxiety disorder, panic disorder, and social anxiety disorder. MDD and anxiety disorders may be treated with pharmacological

2019 CADTH - Optimal Use

39. Esketamine for Treatment-Resistant Depression

Esketamine for Treatment-Resistant Depression Esketamine for Treatment-Resistant Depression | CADTH.ca CADTH Document Viewer Esketamine for Treatment-Resistant Depression Table of Contents Search this document Esketamine for Treatment-Resistant Depression April 2019 Summary Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Approximately 10% to 30% of patients with MDD will not reach complete clinical remission despite multiple antidepressant (...) pharmacologic approaches — this subpopulation is described as having treatment-resistant depression (TRD). TRD is a more challenging depressive disorder to treat and available therapies are often limited by significant psychological and physiological side effects. Esketamine is the S-enantiomer of racemic ketamine and is being developed as a nasal spray device for potential therapeutic use in patients with TRD. It has not yet been approved in any country but is under priority review at Health Canada

2019 CADTH - Issues in Emerging Health Technologies

40. Screening for depression

Screening for depression 1 Translation of the key statement of the final report S16-05 Screening auf Depression (Version 1.0; Status: 27 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-05 Screening for depression 1 Extract of final report S16-05 Version 1.0 Screening (...) for depression 27 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for depression Commissioning agency: Federal Joint Committee Commission awarded on: 27 April 2016 Internal Commission No.: S16-05 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)